Virpax Pharmaceuticals, Inc.
VRPX
$0.30
$0.04417.19%
OTC PK
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 192.98% | -48.01% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 76.40% | -44.36% | |||
| Operating Income | -76.40% | 44.36% | |||
| Income Before Tax | -68.96% | 41.85% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -68.96% | 41.85% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -68.96% | 41.85% | |||
| EBIT | -76.40% | 44.36% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 14.78% | 75.31% | |||
| Normalized Basic EPS | 14.78% | 75.32% | |||
| EPS Diluted | 14.78% | 75.31% | |||
| Normalized Diluted EPS | 14.78% | 75.32% | |||
| Average Basic Shares Outstanding | 98.26% | 135.58% | |||
| Average Diluted Shares Outstanding | 98.26% | 135.58% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||